ClinicalTrials.gg
CompletedNCT01271803Updated Jul 29, 2019Results posted

A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma

A Phase 1 interventional study of Cobimetinib and vemurafenib in Malignant Melanoma, sponsored by Hoffmann-La Roche. Completed at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-29.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
131
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing cobimetinib in Melanoma — 3 open to participants now, 6 under way, 1 of them phase 3. cobimetinib · Melanoma.

Enrollment
5th of 27
131 · median 45
Started
2011
the only one that year
Phase 1
5 of 27
none open now
Registered
1st of 27
by date
Lead sponsor
5 of 27
Hoffmann-La Roche

Among the 27 studies testing cobimetinib in Melanoma, this one is the 5th largest by enrollment, is the only one that started in 2011, is one of 5 in phase 1, and was the 1st registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

3 of the 27 studies testing cobimetinib in Melanoma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cobimetinib

cobimetinib: first FDA approval 2015 (COTELLIC), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing cobimetinib in Melanoma, or all of them as a file.
02

Study summary

This open-label, dose-escalation study of vemurafenib in combination with cobimetinib will evaluate the safety, tolerability and pharmacokinetics in participants with BRAFV600 mutation-positive metastatic melanoma. Participants with previously untreated, BRAFV600E mutation-positive, locally advanced/unresectable or metastatic melanoma or those who have progressed on vemurafenib monotherapy immediately prior to enrolling in this trial are eligible. Participants will be assigned to different cohorts with escalating oral doses of vemurafenib and cobimetinib. This study consists of 2 stages, Stage 1 (Dose Escalation Stage [DES] and Cohort Expansion Stage [CES]) and the anticipated time on study treatment is until disease progression, unacceptable toxicity or any other discontinuation criterion is met.

03

Conditions studied

  • Malignant Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with confirmed melanoma (unresectable Stage IIIc and Stage IV melanoma, as defined by American Joint Committee on Cancer [AJCC])
  • per (RECIST) Version (V) 1.1
  • (ECOG) Performance Status of less than or equal to (\</=) 1
  • Participants must

    1. be previously untreated for locally advanced/unresectable or metastatic melanoma or
    2. previously treated but without prior exposure to any BRAF or MEK inhibitor therapy or
    3. progressed on vemurafenib while participating in a Phase I (including clinical pharmacology studies), II, or III clinical study or expanded access programs (EAP) immediately prior to enrollment in this study or
    4. progressed on vemurafenib administered in a postmarketing setting immediately prior to enrollment in this study.
  • >/=12 weeks

Exclusion criteria

Exclusion Criteria:

  • History of prior significant toxicity from another RAF or MEK pathway inhibitor requiring discontinuation of treatment
  • Palliative radiotherapy within 2 weeks prior to first dose of study drug treatment
  • Experimental therapy within 4 weeks prior to first dose of study drug treatment except vemurafenib
  • Major surgery within 4 weeks of first dose of study drug treatment or planning a major surgery during the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
131 participants (actual)

Study arms

  • Experimental
    DES (Cohort 1): 60 mg Cobimetinib + 720 mg Vemurafenib

    Participants will receive oral 60 milligrams (mg) cobimetinib once daily (QD) on Days 1-14, followed by 14 days off on Days 15-28 (14/14 dosing schedule) and oral 720 mg vemurafenib twice daily (BID) on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.

    Drug: Cobimetinib · Drug: vemurafenib

  • Experimental
    DES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib

    Participants will receive oral 60 mg cobimetinib QD on Days 1-21, followed by 7 days off on Days 22-28 (21/7 dosing schedule) and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.

    Drug: Cobimetinib · Drug: vemurafenib

  • Experimental
    DES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib

    Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.

    Drug: Cobimetinib · Drug: vemurafenib

  • Experimental
    DES (Cohort 1C): 60 mg Cobimetinib + 720 mg Vemurafenib

    Participants will receive oral 60 mg cobimetinib QD on Days 1-28 (28/0 dosing schedule) and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.

    Drug: Cobimetinib · Drug: vemurafenib

  • Experimental
    DES (Cohort 1D): 60 mg Cobimetinib + 960 mg Vemurafenib

    Participants will receive oral 60 mg cobimetinib QD on 28/0 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.

    Drug: Cobimetinib · Drug: vemurafenib

  • Experimental
    DES (Cohort 2): 80 mg Cobimetinib + 720 mg Vemurafenib

    Participants will receive oral 80 mg cobimetinib QD on 14/14 dosing schedule and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.

    Drug: Cobimetinib · Drug: vemurafenib

  • Experimental
    DES (Cohort 2A): 100 mg Cobimetinib + 720 mg Vemurafenib

    Participants will receive oral 100 mg cobimetinib QD on 14/14 dosing schedule and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.

    Drug: Cobimetinib · Drug: vemurafenib

  • Experimental
    DES (Cohort 3): 60 mg Cobimetinib + 960 mg Vemurafenib

    Participants will receive oral 60 mg cobimetinib QD on 14/14 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.

    Drug: Cobimetinib · Drug: vemurafenib

  • Experimental
    DES (Cohort 4): 80 mg Cobimetinib + 960 mg Vemurafenib

    Participants will receive oral 80 mg cobimetinib QD on 14/14 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.

    Drug: Cobimetinib · Drug: vemurafenib

  • Experimental
    Cobimetinib Monotherapy (100 mg or 60 mg)

    Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule, or oral 100 mg cobimetinib QD on 14/14 dosing schedule of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.

    Drug: Cobimetinib

  • Experimental
    CES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib

    Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.

    Drug: Cobimetinib · Drug: vemurafenib

  • Experimental
    CES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib

    Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.

    Drug: Cobimetinib · Drug: vemurafenib

Interventions

  • Participants will receive cobimetinib 60 to 100 mg at any of the 3 dosing schedules with or without vemurafenib in cycles of 28 days each until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.

    Also known as: GDC-0973

  • Participants will receive vemurafenib 720 or 960 mg along with cobimetinib in cycles of 28 days each until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicities (DLTs) During DES in Combination Cohorts

    DLT is defined as 1 of the following toxicities considered by the investigator to be related to study treatment: a) Grade 3 nausea, vomiting or diarrhea that resolved to Grade less than or equal to (≤) 1 within 7 days, b) Grade 3 rash or photosensitivity that resolved to Grade ≤2 within 7 days, c) Grade 3 cutaneous squamous cell carcinoma (cuSCC) that was subsequently resected, d) Grade greater than or equal to (≥) 3 fatigue or hyperuricemia that resolved to Grade ≤2 within 7 days, e) Grade 3 fever, f) Grade 3 or 4 elevation of serum creatine phosphokinase (CPK) levels, which is asymptomatic, deemed by the investigator to be clinically insignificant and that returned to Grade ≤2 during the 14-day cobimetinib treatment holiday, g) Grade ≥3 febrile neutropenia, h) Grade ≥4 neutropenia (absolute neutrophil count \[ANC\] less than \<500/microliter \[μL\]), i) Grade ≥4 thrombocytopenia, j) Grade ≥4 anemia, k) Grade ≥3 elevation of total bilirubin, hepatic transaminase or alkaline phosphatase.

    Time frame: 28 Days

  2. Maximum Tolerated Doses (MTD) of Vemurafenib and Cobimetinib When Administered in Combination in DES

    The highest dose level(s) at which fewer than one-third of participants experienced a DLT was declared the MTD. DLT is defined as 1 of the following toxicities considered by the investigator to be related to study treatment: a) Grade 3 nausea, vomiting or diarrhea that resolved to Grade ≤1 within 7 days, b) Grade 3 rash/photosensitivity that resolved to Grade ≤2 within 7 days, c) Grade 3 cuSCC that was subsequently resected, d) Grade ≥3 fatigue/hyperuricemia that resolved to Grade ≤2 within 7 days, e) Grade 3 fever, f) Grade 3 or 4 elevation of serum CPK levels, which is asymptomatic, deemed to be clinically insignificant and returns to Grade ≤2 during the 14-day cobimetinib treatment holiday, g) Grade ≥3 febrile neutropenia, h) Grade ≥4 neutropenia (ANC \<500/ μL), i) Grade ≥4 thrombocytopenia, j) Grade ≥4 anemia, k) Grade ≥3 elevation of total bilirubin, hepatic transaminase or alkaline phosphatase.

    Time frame: 28 Days

  3. Maximum Plasma Concentration (Cmax) of Cobimetinib on Day 1, Cycle 1

    Time frame: Cycle 1: predose (0 hours [hr]) on Days 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1

  4. Cmax of Cobimetinib on Day 1, Cycle 1 in Cohort 3

    Time frame: Cycle 1: predose (0 hr) on Days 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1

  5. Time Taken to Reach Maximum Plasma Concentration (Tmax) of Cobimetinib on Day 1, Cycle 1

    Time frame: Cycle 1: predose (0 hr) on Days 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1

  6. Area Under Concentration Versus Time Curve (AUC) Over a Period of 24 Hours (AUC0-24) of Cobimetinib on Day 1, Cycle 1

    Time frame: Cycle 1: predose (0 hr) on Days 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1

  7. AUC0-24 of Cobimetinib on Day 1, Cycle 1 of Cohort 3

    Time frame: Cycle 1: predose (0 hr) on Days 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1

  8. Cmax of Cobimetinib on Day 14 (Steady State), Cycle 1

    Time frame: Cycle 1: predose (0 hr) on Days 8, 14; 0.5, 1, 2, 4, 6 hr postdose on Day 14

  9. Tmax of Cobimetinib on Day 14 (Steady State), Cycle 1

    Time frame: Cycle 1: predose (0 hr) on Days 8, 14; 0.5, 1, 2, 4, 6 hr postdose on Day 14

  10. AUC0-24 of Cobimetinib on Day 14, Cycle 1

    Time frame: Cycle 1: predose (0 hr) on Days 8, 14; 0.5, 1, 2, 4, 6 hr postdose on Day 14

  11. Clearance (CL) of Cobimetinib on Day 14 (Steady State), Cycle 1

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

    Time frame: Cycle 1: predose (0 hr) on Days 8, 14; 0.5, 1, 2, 4, 6 hr postdose on Day 14

  12. Cmax of Vemurafenib on Day -1, Cycle 1 in Participants Previously Treated With Vemurafenib Prior to Enrollment Into This Study

    Time frame: Predose (0 hr) on Days -1, 1; 2, 4, 6, 8 hr postdose on Day -1

  13. Cmax of Vemurafenib on Day -1, Cycle 1 of Cohorts 1C and 2A in Participants Previously Treated With Vemurafenib Prior to Enrollment Into This Study

    Time frame: Predose (0 hr) on Day -1, 1; 2, 4, 6, 8 hr postdose on Day -1

  14. Tmax of Vemurafenib on Day -1, Cycle 1 in Participants Previously Treated With Vemurafenib Prior to Enrollment Into This Study

    Time frame: Predose (0 hr) on Day -1, 1; 2, 4, 6, 8 hr postdose on Day -1

  15. Cmax of Vemurafenib on Day 1, Cycle 1 in BRAFi-naïve Participants

    Time frame: Predose (0 hr) on Day 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1

  16. Cmax of Vemurafenib on Day 1, Cycle 1 in Cohort 1A in BRAFi-naïve Participants

    Time frame: Predose (0 hr) on Day 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1

  17. Tmax of Vemurafenib on Day 1, Cycle 1 in BRAFi-naïve Participants

    Time frame: Predose (0 hr) on Day 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1

  18. Cmax of Vemurafenib on Day 14, Cycle 1

    Time frame: Predose (0 hr) on Days 14, 15; 0.5, 1, 2, 4, 6, 8 hr postdose on Day 14

  19. Tmax of Vemurafenib on Day 14, Cycle 1

    Time frame: Predose (0 hr) on Days 14, 15; 0.5, 1, 2, 4, 6, 8 hr postdose on Day 14

Secondary outcomes

  1. Percentage of Participants With an Objective Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version (V) 1.1

    Tumor response of CR or PR is considered as objective response. CR: disappearance of all target lesions, reduction in short axis \<10 millimeters in pathological lymph nodes (target and non-target lesions); PR: at least a 30 percent (%) decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. Responses were confirmed by repeat assessments ≥4 weeks after initial documentation.

    Time frame: Assessed at screening (within 28 days prior to initiation of Cycle 1), every 6 weeks thereafter until disease progression (up to 82 months)

  2. Percentage of Participants With Disease Progression According to RECIST V 1.1

    Progressive disease (PD) according to RECIST V 1.1: at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (nadir), including baseline; in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm; appearance of 1 or more lesions is also considered as progression.

    Time frame: Assessed at screening (within 28 days prior to initiation of Cycle 1), every 6 weeks thereafter until disease progression or death (up to 82 months)

  3. Median Duration of Response (DOR)

    Duration of response, defined as the time from first occurrence of a documented objective response until the time of disease progression, as determined by investigator review of tumor assessments using RECIST v 1.1, or death from any cause during the study (that is within 30 days after the last dose of study treatment).

    Time frame: Time from first occurrence of objective response until the time of disease progression or death from any cause (up to 82 months)

  4. Overall Survival (OS)

    OS was defined as the time from the date of randomization to the date of death due to any cause. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up. OS analyzed using Kaplan-Meier estimate.

    Time frame: Assessed at screening (within 28 days prior to initiation of Cycle 1), every 6 weeks thereafter until disease progression or death (up to 82 months)

  5. Average Percent Change From Baseline in Fluorodeoxyglucose-positron Emission Tomography (FDG-PET) at Cycle 1 and Cycle 2

    The pharmacodynamic effect of cobimetinib in combination with vemurafenib was assessed by measuring changes in FDG uptake as characterized by the lean body mass corrected (LBM) maximum standardized uptake value (SUV max) measurement using FDG-PET. Post-baseline timepoint Cycle 1 was averaged between Days 10 to 14 and Cycle 2 for Days 14+7.

    Time frame: Cycle 1 (Days 10 to 14), Cycle 2 (Days 14+7)

  6. Pharmacodynamics: Number of Participants With Mitogen-Activated Protein Kinase (MAPK) Inhibition, as Assessed by Immunohistochemistry (IHC)

    Changes in effector molecules of the MAPK pathway that are directly or indirectly affected by BRAF and MEK inhibition (including but not limited to ERK and phosphorylated ERK and MEK) by IHC using biopsies at baseline, between Days 10-14 of Cycle 1, and at disease progression. IHC is a staining process performed on fresh/frozen tumor tissue samples.

    Time frame: At baseline; Cycle 1: Day 14; at disease progression (Up to 32 months)

07

Results

Posted Jun 17, 2016

Participant flow

Study included two stages. Stage 1: dose escalation stage (DES), consisted of 9 "Cobimetinib + Vemurafenib" combination arms and 1 Cobimetinib monotherapy. Stage 2: cohort expansion stage (CES), consisted of 2 "Cobimetinib + Vemurafenib" combination arms, treated with recommended phase 2 dose.

Participant flow — Overall Study
MilestoneVemurafenib PD ParticipantsBRAFi-naïve ParticipantsCobimetinib Monotherapy (100 mg or 60 mg)
Started66632
Completed11240
Not completed55392
Withdrew: Progressive disease002
Withdrew: Death53340
Withdrew: Withdrawal by subject150
Withdrew: Lost to follow-up100

Outcome measures

PrimaryNumber of Participants With Dose-Limiting Toxicities (DLTs) During DES in Combination Cohorts

DLT is defined as 1 of the following toxicities considered by the investigator to be related to study treatment: a) Grade 3 nausea, vomiting or diarrhea that resolved to Grade less than or equal to (≤) 1 within 7 days, b) Grade 3 rash or photosensitivity that resolved to Grade ≤2 within 7 days, c) Grade 3 cutaneous squamous cell carcinoma (cuSCC) that was subsequently resected, d) Grade greater than or equal to (≥) 3 fatigue or hyperuricemia that resolved to Grade ≤2 within 7 days, e) Grade 3 fever, f) Grade 3 or 4 elevation of serum creatine phosphokinase (CPK) levels, which is asymptomatic, deemed by the investigator to be clinically insignificant and that returned to Grade ≤2 during the 14-day cobimetinib treatment holiday, g) Grade ≥3 febrile neutropenia, h) Grade ≥4 neutropenia (absolute neutrophil count \[ANC\] less than \<500/microliter \[μL\]), i) Grade ≥4 thrombocytopenia, j) Grade ≥4 anemia, k) Grade ≥3 elevation of total bilirubin, hepatic transaminase or alkaline phosphatase.

Time frame:
28 Days
Reported as:
Number · participants
Number of Participants With Dose-Limiting Toxicities (DLTs) During DES in Combination Cohorts
participantsDES (Cohort 1): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1A): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1B): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 1C): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1D): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 2): 80 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 2A): 100 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 3): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 4): 80 mg Cobimetinib + 960 mg Vemurafenib
Number of Participants With Dose-Limiting Toxicities (DLTs) During DES in Combination Cohorts001020001
PrimaryMaximum Tolerated Doses (MTD) of Vemurafenib and Cobimetinib When Administered in Combination in DES

The highest dose level(s) at which fewer than one-third of participants experienced a DLT was declared the MTD. DLT is defined as 1 of the following toxicities considered by the investigator to be related to study treatment: a) Grade 3 nausea, vomiting or diarrhea that resolved to Grade ≤1 within 7 days, b) Grade 3 rash/photosensitivity that resolved to Grade ≤2 within 7 days, c) Grade 3 cuSCC that was subsequently resected, d) Grade ≥3 fatigue/hyperuricemia that resolved to Grade ≤2 within 7 days, e) Grade 3 fever, f) Grade 3 or 4 elevation of serum CPK levels, which is asymptomatic, deemed to be clinically insignificant and returns to Grade ≤2 during the 14-day cobimetinib treatment holiday, g) Grade ≥3 febrile neutropenia, h) Grade ≥4 neutropenia (ANC \<500/ μL), i) Grade ≥4 thrombocytopenia, j) Grade ≥4 anemia, k) Grade ≥3 elevation of total bilirubin, hepatic transaminase or alkaline phosphatase.

Time frame:
28 Days
Reported as:
Number · mg
Maximum Tolerated Doses (MTD) of Vemurafenib and Cobimetinib When Administered in Combination in DES
mgDose Escalation Stage (Stage 1)
Cobimetinib dose (21/7 dosing schedule)60
Vemurafenib dose (21/7 dosing schedule)960
PrimaryMaximum Plasma Concentration (Cmax) of Cobimetinib on Day 1, Cycle 1
Time frame:
Cycle 1: predose (0 hours [hr]) on Days 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Maximum Plasma Concentration (Cmax) of Cobimetinib on Day 1, Cycle 1
nanograms per milliliter (ng/mL)DES (Cohort 1): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1A): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1B): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 1C): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1D): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 2): 80 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 2A): 100 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 4): 80 mg Cobimetinib + 960 mg VemurafenibCES (Cohort 1A): 60 mg Cobimetinib + 720 mg VemurafenibCES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib
Maximum Plasma Concentration (Cmax) of Cobimetinib on Day 1, Cycle 1159 ± 110146 ± 100121 ± 96136 ± 81130 ± 53133 ± 37146 ± 7993.6 ± 2684.3 ± 67105 ± 64
PrimaryCmax of Cobimetinib on Day 1, Cycle 1 in Cohort 3
Time frame:
Cycle 1: predose (0 hr) on Days 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1
Reported as:
Mean · ng/mL
Cmax of Cobimetinib on Day 1, Cycle 1 in Cohort 3
ng/mLDES (Cohort 3): 60 mg Cobimetinib + 960 mg Vemurafenib
Cmax of Cobimetinib on Day 1, Cycle 1 in Cohort 351.6 ± 50.1
PrimaryTime Taken to Reach Maximum Plasma Concentration (Tmax) of Cobimetinib on Day 1, Cycle 1
Time frame:
Cycle 1: predose (0 hr) on Days 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1
Reported as:
Median · hours
Time Taken to Reach Maximum Plasma Concentration (Tmax) of Cobimetinib on Day 1, Cycle 1
hoursDES (Cohort 1): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1A): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1B): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 1C): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1D): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 2): 80 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 2A): 100 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 3): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 4): 80 mg Cobimetinib + 960 mg VemurafenibCES (Cohort 1A): 60 mg Cobimetinib + 720 mg VemurafenibCES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib
Time Taken to Reach Maximum Plasma Concentration (Tmax) of Cobimetinib on Day 1, Cycle 14.00 (2.0 to 5.5)4.0 (2.0 to 27)4.00 (1.0 to 25)2.03 (2.0 to 24)3.99 (1.0 to 6.2)4.02 (4.0 to 4.1)4.03 (4.0 to 4.3)3.05 (2.0 to 4.1)4.00 (2.0 to 6.0)4.00 (0.5 to 6.0)4.00 (1.0 to 24)
PrimaryArea Under Concentration Versus Time Curve (AUC) Over a Period of 24 Hours (AUC0-24) of Cobimetinib on Day 1, Cycle 1
Time frame:
Cycle 1: predose (0 hr) on Days 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1
Reported as:
Geometric mean · nanograms*hours per milliliter (ng*h/mL)
Area Under Concentration Versus Time Curve (AUC) Over a Period of 24 Hours (AUC0-24) of Cobimetinib on Day 1, Cycle 1
nanograms*hours per milliliter (ng*h/mL)DES (Cohort 1): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1A): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1B): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 1C): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1D): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 2): 80 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 2A): 100 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 4): 80 mg Cobimetinib + 960 mg VemurafenibCES (Cohort 1A): 60 mg Cobimetinib + 720 mg VemurafenibCES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib
Area Under Concentration Versus Time Curve (AUC) Over a Period of 24 Hours (AUC0-24) of Cobimetinib on Day 1, Cycle 12280 ± 901990 ± 991790 ± 881300 ± 351850 ± 351600 ± 292300 ± 1001410 ± 291220 ± 631530 ± 65
PrimaryAUC0-24 of Cobimetinib on Day 1, Cycle 1 of Cohort 3
Time frame:
Cycle 1: predose (0 hr) on Days 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1
Reported as:
Mean · ng*h/mL
AUC0-24 of Cobimetinib on Day 1, Cycle 1 of Cohort 3
ng*h/mLDES (Cohort 3): 60 mg Cobimetinib + 960 mg Vemurafenib
AUC0-24 of Cobimetinib on Day 1, Cycle 1 of Cohort 3727 ± 556
PrimaryCmax of Cobimetinib on Day 14 (Steady State), Cycle 1
Time frame:
Cycle 1: predose (0 hr) on Days 8, 14; 0.5, 1, 2, 4, 6 hr postdose on Day 14
Reported as:
Geometric mean · ng/mL
Cmax of Cobimetinib on Day 14 (Steady State), Cycle 1
ng/mLDES (Cohort 1): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1A): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1B): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 1C): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1D): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 2): 80 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 2A): 100 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 3): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 4): 80 mg Cobimetinib + 960 mg VemurafenibCES (Cohort 1A): 60 mg Cobimetinib + 720 mg VemurafenibCES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib
Cmax of Cobimetinib on Day 14 (Steady State), Cycle 1342 ± 130307 ± 75232 ± 80239 ± 14414 ± 16195 ± 48383 ± 50215 ± 19350 ± 37177 ± 74200 ± 91
PrimaryTmax of Cobimetinib on Day 14 (Steady State), Cycle 1
Time frame:
Cycle 1: predose (0 hr) on Days 8, 14; 0.5, 1, 2, 4, 6 hr postdose on Day 14
Reported as:
Median · hours
Tmax of Cobimetinib on Day 14 (Steady State), Cycle 1
hoursDES (Cohort 1): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1A): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1B): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 1C): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1D): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 2): 80 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 2A): 100 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 3): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 4): 80 mg Cobimetinib + 960 mg VemurafenibCES (Cohort 1A): 60 mg Cobimetinib + 720 mg VemurafenibCES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib
Tmax of Cobimetinib on Day 14 (Steady State), Cycle 12.0 (0.98 to 4.0)3.98 (2.0 to 7.0)4.02 (0.5 to 8.0)4.00 (4.0 to 4.1)6.00 (4.9 to 6.1)6.0 (2.0 to 6.0)4.03 (2.2 to 6.1)4.08 (4.0 to 6.1)4.00 (3.9 to 4.1)4.04 (2.0 to 8.0)4.00 (0.0 to 8.0)
PrimaryAUC0-24 of Cobimetinib on Day 14, Cycle 1
Time frame:
Cycle 1: predose (0 hr) on Days 8, 14; 0.5, 1, 2, 4, 6 hr postdose on Day 14
Reported as:
Geometric mean · ng*h/mL
AUC0-24 of Cobimetinib on Day 14, Cycle 1
ng*h/mLDES (Cohort 1): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1A): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1B): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 1C): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1D): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 2): 80 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 2A): 100 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 3): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 4): 80 mg Cobimetinib + 960 mg VemurafenibCES (Cohort 1A): 60 mg Cobimetinib + 720 mg VemurafenibCES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib
AUC0-24 of Cobimetinib on Day 14, Cycle 15180 ± 1704800 ± 763540 ± 834500 ± 177020 ± 273820 ± 486360 ± 463520 ± 355790 ± 362540 ± 843220 ± 124
PrimaryClearance (CL) of Cobimetinib on Day 14 (Steady State), Cycle 1

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

Time frame:
Cycle 1: predose (0 hr) on Days 8, 14; 0.5, 1, 2, 4, 6 hr postdose on Day 14
Reported as:
Geometric mean · Liters per hour (L/h)
Clearance (CL) of Cobimetinib on Day 14 (Steady State), Cycle 1
Liters per hour (L/h)DES (Cohort 1): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1A): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1B): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 1C): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1D): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 2): 80 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 2A): 100 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 3): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 4): 80 mg Cobimetinib + 960 mg VemurafenibCES (Cohort 1A): 60 mg Cobimetinib + 720 mg VemurafenibCES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib
Clearance (CL) of Cobimetinib on Day 14 (Steady State), Cycle 111.6 ± 17012.5 ± 7617.0 ± 8313.3 ± 178.55 ± 2721.0 ± 4815.7 ± 4617.0 ± 3513.8 ± 3623.6 ± 8418.6 ± 124
PrimaryCmax of Vemurafenib on Day -1, Cycle 1 in Participants Previously Treated With Vemurafenib Prior to Enrollment Into This Study
Time frame:
Predose (0 hr) on Days -1, 1; 2, 4, 6, 8 hr postdose on Day -1
Reported as:
Geometric mean · micrograms per milliliter (mcg/mL)
Cmax of Vemurafenib on Day -1, Cycle 1 in Participants Previously Treated With Vemurafenib Prior to Enrollment Into This Study
micrograms per milliliter (mcg/mL)DES (Cohort 1): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1A): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1B): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 2): 80 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 3): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 4): 80 mg Cobimetinib + 960 mg VemurafenibCES (Cohort 1A): 60 mg Cobimetinib + 720 mg VemurafenibCES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib
Cmax of Vemurafenib on Day -1, Cycle 1 in Participants Previously Treated With Vemurafenib Prior to Enrollment Into This Study36.4 ± 5834.3 ± 3460.9 ± 3256.0 ± 1636.4 ± 1948.2 ± NA40.9 ± 11048.6 ± 37
PrimaryCmax of Vemurafenib on Day -1, Cycle 1 of Cohorts 1C and 2A in Participants Previously Treated With Vemurafenib Prior to Enrollment Into This Study
Time frame:
Predose (0 hr) on Day -1, 1; 2, 4, 6, 8 hr postdose on Day -1
Reported as:
Mean · mcg/mL
Cmax of Vemurafenib on Day -1, Cycle 1 of Cohorts 1C and 2A in Participants Previously Treated With Vemurafenib Prior to Enrollment Into This Study
mcg/mLDES (Cohort 1C): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 2A): 100 mg Cobimetinib + 720 mg Vemurafenib
Cmax of Vemurafenib on Day -1, Cycle 1 of Cohorts 1C and 2A in Participants Previously Treated With Vemurafenib Prior to Enrollment Into This Study38.8 ± 9.6148.8 ± 35.4
PrimaryTmax of Vemurafenib on Day -1, Cycle 1 in Participants Previously Treated With Vemurafenib Prior to Enrollment Into This Study
Time frame:
Predose (0 hr) on Day -1, 1; 2, 4, 6, 8 hr postdose on Day -1
Reported as:
Median · hours
Tmax of Vemurafenib on Day -1, Cycle 1 in Participants Previously Treated With Vemurafenib Prior to Enrollment Into This Study
hoursDES (Cohort 1): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1A): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1B): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 1C): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 2): 80 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 2A): 100 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 3): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 4): 80 mg Cobimetinib + 960 mg VemurafenibCES (Cohort 1A): 60 mg Cobimetinib + 720 mg VemurafenibCES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib
Tmax of Vemurafenib on Day -1, Cycle 1 in Participants Previously Treated With Vemurafenib Prior to Enrollment Into This Study2.42 (1.3 to 4.5)2.50 (0.7 to 7.5)3.69 (1.1 to 11)4.55 (3.1 to 6.0)2.03 (0.9 to 2.5)1.65 (1.3 to 2.0)1.92 (0.6 to 4.8)0.83 (NA to NA)2.33 (0.3 to 8.1)1.93 (0.6 to 7.5)
PrimaryCmax of Vemurafenib on Day 1, Cycle 1 in BRAFi-naïve Participants
Time frame:
Predose (0 hr) on Day 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1
Reported as:
Geometric mean · mcg/mL
Cmax of Vemurafenib on Day 1, Cycle 1 in BRAFi-naïve Participants
mcg/mLDES (Cohort 1B): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 1C): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1D): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 2A): 100 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 4): 80 mg Cobimetinib + 960 mg VemurafenibCES (Cohort 1A): 60 mg Cobimetinib + 720 mg VemurafenibCES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib
Cmax of Vemurafenib on Day 1, Cycle 1 in BRAFi-naïve Participants3.99 ± 732.31 ± NA4.16 ± 781.25 ± NA2.55 ± 1702.60 ± 702.78 ± 57
PrimaryCmax of Vemurafenib on Day 1, Cycle 1 in Cohort 1A in BRAFi-naïve Participants
Time frame:
Predose (0 hr) on Day 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1
Reported as:
Mean · mcg/mL
Cmax of Vemurafenib on Day 1, Cycle 1 in Cohort 1A in BRAFi-naïve Participants
mcg/mLDES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib
Cmax of Vemurafenib on Day 1, Cycle 1 in Cohort 1A in BRAFi-naïve Participants2.08 ± 1.64
PrimaryTmax of Vemurafenib on Day 1, Cycle 1 in BRAFi-naïve Participants
Time frame:
Predose (0 hr) on Day 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1
Reported as:
Median · hours
Tmax of Vemurafenib on Day 1, Cycle 1 in BRAFi-naïve Participants
hoursDES (Cohort 1A): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1B): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 1C): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1D): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 2A): 100 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 4): 80 mg Cobimetinib + 960 mg VemurafenibCES (Cohort 1A): 60 mg Cobimetinib + 720 mg VemurafenibCES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib
Tmax of Vemurafenib on Day 1, Cycle 1 in BRAFi-naïve Participants5.2 (4.4 to 6.0)4.15 (1.0 to 6.0)5.17 (NA to NA)5.33 (2.0 to 6.2)2.08 (NA to NA)4.00 (2.0 to 6.0)4.00 (2.0 to 6.0)4.00 (1.0 to 24)
PrimaryCmax of Vemurafenib on Day 14, Cycle 1
Time frame:
Predose (0 hr) on Days 14, 15; 0.5, 1, 2, 4, 6, 8 hr postdose on Day 14
Reported as:
Geometric mean · mcg/mL
Cmax of Vemurafenib on Day 14, Cycle 1
mcg/mLDES (Cohort 1): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1A): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1B): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 1C): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1D): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 2): 80 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 2A): 100 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 3): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 4): 80 mg Cobimetinib + 960 mg VemurafenibCES (Cohort 1A): 60 mg Cobimetinib + 720 mg VemurafenibCES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib
Cmax of Vemurafenib on Day 14, Cycle 134.7 ± 4129.4 ± 2543.7 ± 3731.7 ± 4251.3 ± 1443.6 ± 4530.6 ± 5340.9 ± 2033.7 ± 1633.3 ± 5836.3 ± 29
PrimaryTmax of Vemurafenib on Day 14, Cycle 1
Time frame:
Predose (0 hr) on Days 14, 15; 0.5, 1, 2, 4, 6, 8 hr postdose on Day 14
Reported as:
Median · hours
Tmax of Vemurafenib on Day 14, Cycle 1
hoursDES (Cohort 1): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1A): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1B): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 1C): 60 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 1D): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 2): 80 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 2A): 100 mg Cobimetinib + 720 mg VemurafenibDES (Cohort 3): 60 mg Cobimetinib + 960 mg VemurafenibDES (Cohort 4): 80 mg Cobimetinib + 960 mg VemurafenibCES (Cohort 1A): 60 mg Cobimetinib + 720 mg VemurafenibCES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib
Tmax of Vemurafenib on Day 14, Cycle 11.98 (0.0 to 7.7)2.15 (0.0 to 7.3)1.95 (0.0 to 8.0)1.98 (0.3 to 6.5)0.33 (0.2 to 8.2)5.6 (1.7 to 5.6)1.05 (0.0 to 6.4)1.83 (0.8 to 4.4)1.85 (0.1 to 4.0)1.17 (0.0 to 7.9)1.90 (0.0 to 7.6)
SecondaryPercentage of Participants With an Objective Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version (V) 1.1

Tumor response of CR or PR is considered as objective response. CR: disappearance of all target lesions, reduction in short axis \<10 millimeters in pathological lymph nodes (target and non-target lesions); PR: at least a 30 percent (%) decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. Responses were confirmed by repeat assessments ≥4 weeks after initial documentation.

Time frame:
Assessed at screening (within 28 days prior to initiation of Cycle 1), every 6 weeks thereafter until disease progression (up to 82 months)
Reported as:
Number · percentage of participants
Percentage of Participants With an Objective Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version (V) 1.1
percentage of participantsVemurafenib PD ParticipantsBRAFi-naïve Participants
Percentage of Participants With an Objective Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version (V) 1.115.2 (7.5 to 25.5)87.3 (76.7 to 94.4)
SecondaryPercentage of Participants With Disease Progression According to RECIST V 1.1

Progressive disease (PD) according to RECIST V 1.1: at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (nadir), including baseline; in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm; appearance of 1 or more lesions is also considered as progression.

Time frame:
Assessed at screening (within 28 days prior to initiation of Cycle 1), every 6 weeks thereafter until disease progression or death (up to 82 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Progression According to RECIST V 1.1
percentage of participantsVemurafenib PD ParticipantsBRAFi-naïve Participants
Percentage of Participants With Disease Progression According to RECIST V 1.136.43.2
SecondaryMedian Duration of Response (DOR)

Duration of response, defined as the time from first occurrence of a documented objective response until the time of disease progression, as determined by investigator review of tumor assessments using RECIST v 1.1, or death from any cause during the study (that is within 30 days after the last dose of study treatment).

Time frame:
Time from first occurrence of objective response until the time of disease progression or death from any cause (up to 82 months)
Reported as:
Median · months
Median Duration of Response (DOR)
monthsVemurafenib PD ParticipantsBRAFi-naïve Participants
Median Duration of Response (DOR)6.8 (4.9 to 10.4)14.3 (9.7 to 23)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of randomization to the date of death due to any cause. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up. OS analyzed using Kaplan-Meier estimate.

Time frame:
Assessed at screening (within 28 days prior to initiation of Cycle 1), every 6 weeks thereafter until disease progression or death (up to 82 months)
Reported as:
Median · months
Overall Survival (OS)
monthsVemurafenib PD ParticipantsBRAFi-naïve Participants
Overall Survival (OS)8.5 (1.6 to 76.4)31.8 (2.7 to 69.2)
SecondaryAverage Percent Change From Baseline in Fluorodeoxyglucose-positron Emission Tomography (FDG-PET) at Cycle 1 and Cycle 2

The pharmacodynamic effect of cobimetinib in combination with vemurafenib was assessed by measuring changes in FDG uptake as characterized by the lean body mass corrected (LBM) maximum standardized uptake value (SUV max) measurement using FDG-PET. Post-baseline timepoint Cycle 1 was averaged between Days 10 to 14 and Cycle 2 for Days 14+7.

Time frame:
Cycle 1 (Days 10 to 14), Cycle 2 (Days 14+7)
Reported as:
Mean · Percent change in FDG-PET
Average Percent Change From Baseline in Fluorodeoxyglucose-positron Emission Tomography (FDG-PET) at Cycle 1 and Cycle 2
Percent change in FDG-PETVemurafenib PD ParticipantsBRAFi-naïve Participants
Baseline (n=63,63)8.75 ± 5.558.19 ± 5.00
Percent Change at Cycle 1 (Days 10-14) (n=59,60)-43.33 ± 26.00-65.74 ± 14.82
Percent Change at Cycle 2 (Days 14+7) (n=50,56)-33.09 ± 35.18-70.73 ± 17.05
SecondaryPharmacodynamics: Number of Participants With Mitogen-Activated Protein Kinase (MAPK) Inhibition, as Assessed by Immunohistochemistry (IHC)

Changes in effector molecules of the MAPK pathway that are directly or indirectly affected by BRAF and MEK inhibition (including but not limited to ERK and phosphorylated ERK and MEK) by IHC using biopsies at baseline, between Days 10-14 of Cycle 1, and at disease progression. IHC is a staining process performed on fresh/frozen tumor tissue samples.

Time frame:
At baseline; Cycle 1: Day 14; at disease progression (Up to 32 months)
Reported as:
Number · participants
Pharmacodynamics: Number of Participants With Mitogen-Activated Protein Kinase (MAPK) Inhibition, as Assessed by Immunohistochemistry (IHC)
participantsVemurafenib PD ParticipantsBRAFi-naïve Participants
Pharmacodynamics: Number of Participants With Mitogen-Activated Protein Kinase (MAPK) Inhibition, as Assessed by Immunohistochemistry (IHC)75

Adverse events

Collected over Up to 82 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vemurafenib PD Participants—21/66 (31.8%)64/66 (97%)
BRAFi-naïve Participants—36/63 (57.1%)63/63 (100%)
Cobimetinib Monotherapy (100 mg or 60 mg)—0/2 (0%)2/2 (100%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
EventVemurafenib PD ParticipantsBRAFi-naïve ParticipantsCobimetinib Monotherapy (100 mg or 60 mg)
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/667/630/2
SeizureNervous system disorders1/665/630/2
CellulitisInfections and infestations0/664/630/2
PyrexiaGeneral disorders1/662/630/2
PneumoniaInfections and infestations2/662/630/2
SepsisInfections and infestations0/662/630/2
Urinary tract infectionInfections and infestations0/662/630/2
HyponatraemiaMetabolism and nutrition disorders0/662/630/2
Back painMusculoskeletal and connective tissue disorders0/662/630/2
Renal failureRenal and urinary disorders0/662/630/2
Most frequent other events
Showing 10 of 110
Most frequent other events
EventVemurafenib PD ParticipantsBRAFi-naïve ParticipantsCobimetinib Monotherapy (100 mg or 60 mg)
DiarrhoeaGastrointestinal disorders31/6652/632/2
FatigueGeneral disorders18/6646/631/2
Photosensitivity reactionSkin and subcutaneous tissue disorders12/6644/630/2
NauseaGastrointestinal disorders22/6637/631/2
RashSkin and subcutaneous tissue disorders18/6633/631/2
Dermatitis acneiformSkin and subcutaneous tissue disorders6/6622/631/2
AlopeciaSkin and subcutaneous tissue disorders7/669/631/2
VomitingGastrointestinal disorders13/6630/631/2
Abdominal painGastrointestinal disorders10/6613/631/2
ConstipationGastrointestinal disorders10/6613/631/2

Baseline characteristics

Demographic data was not reported across dose/regimen cohort per final analysis, as it was pooled across separately for vemurafenib-PD and BRAFi-naive participants who received cobimetinib and vemurafenib. Data is presented based on the final CSR. As of 2017 per-cohort data were not collected

Age, Continuous
Age, Continuous(years)Vemurafenib PD ParticipantsBRAFi-naïve ParticipantsCobimetinib Monotherapy (100 mg or 60 mg)Total
Mean53.0 ± 14.854.0 ± 13.062.5 ± 9.253.6 ± 13.9
Sex: Female, Male
Sex: Female, Male(Participants)Vemurafenib PD ParticipantsBRAFi-naïve ParticipantsCobimetinib Monotherapy (100 mg or 60 mg)Total
Female2428153
Male4235178
08

Study locations

10 sites
  • UCLA Department of Medicine
    Los Angeles, California 90024, United States
  • University of California at San Francisco
    San Francisco, California 94115, United States
  • The Angeles Clinic and Research Institute, Santa Monica Office
    Santa Monica, California 90025, United States
  • University of Colorado; Anschutz Cancer Pavilion
    Aurora, Colorado 80045, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Indiana University - Department of Medicine, Division of Gastroenterology/Hepatology
    Indianapolis, Indiana 46202, United States
  • Karmanos Cancer Inst. ; Hudson Webber; Cancer Research Building
    Detroit, Michigan 48201, United States
  • New York University Medical Center
    New York, New York 10036, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Peter Maccallum Cancer Institute; Medical Oncology
    Melbourne, Victoria 3000, Australia
09

References and documents

Publications

  • Ascierto PA, Ribas A, Larkin J, McArthur GA, Lewis KD, Hauschild A, Flaherty KT, McKenna E, Zhu Q, Mun Y, Dreno B. Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib +/- cobimetinib: a pooled analysis of four clinical trials. J Transl Med. 2020 Aug 3;18(1):294. doi: 10.1186/s12967-020-02458-x. PubMed 32746839 ↗
  • Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, Flaherty L, Logan T, Chmielowski B, Lewis K, Kee D, Boasberg P, Yin M, Chan I, Musib L, Choong N, Puzanov I, McArthur GA. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014 Aug;15(9):954-65. doi: 10.1016/S1470-2045(14)70301-8. Epub 2014 Jul 15. Erratum In: Lancet Oncol. 2014 Sep;15(10):417. PubMed 25037139 ↗
  • Baudy AR, Dogan T, Flores-Mercado JE, Hoeflich KP, Su F, van Bruggen N, Williams SP. FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973. EJNMMI Res. 2012 May 31;2(1):22. doi: 10.1186/2191-219X-2-22. PubMed 22651703 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2011 to primary completion in Oct 2013, 31 months.

Results were first posted in Jun 2016, 2 years 8 months after primary completion.

Of 225 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's 31 months is below that.

Counting every sponsor, half of 411 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2011
First posted
Jan 7, 2011
StartActual
Feb 17, 2011
Primary completionActual
Oct 1, 2013
CompletionActual
Dec 12, 2017
Results first posted
Jun 17, 2016
Last update
Jul 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01271803
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 7, 2011
Start date
Feb 17, 2011
Primary completion
Oct 1, 2013
Completion
Dec 12, 2017
Results posted
Jun 17, 2016
Last update
Jul 29, 2019

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cobimetinib · Vemurafenib

Start the discussion